Cargando…
Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay
[Image: see text] The papain-like protease (PL(pro)) of SARS-CoV-2 is a validated antiviral drug target. Through a fluorescence resonance energy transfer-based high-throughput screening and subsequent lead optimization, we identified several PL(pro) inhibitors including Jun9-72-2 and Jun9-75-4 with...
Autores principales: | Ma, Chunlong, Sacco, Michael Dominic, Xia, Zilei, Lambrinidis, George, Townsend, Julia Alma, Hu, Yanmei, Meng, Xiangzhi, Szeto, Tommy, Ba, Mandy, Zhang, Xiujun, Gongora, Maura, Zhang, Fushun, Marty, Michael Thomas, Xiang, Yan, Kolocouris, Antonios, Chen, Yu, Wang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265724/ https://www.ncbi.nlm.nih.gov/pubmed/34341772 http://dx.doi.org/10.1021/acscentsci.1c00519 |
Ejemplares similares
-
Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay
por: Xia, Zilei, et al.
Publicado: (2021) -
FlipGFP protease assay for evaluating in vitro inhibitory activity against SARS-CoV-2 M(pro) and PL(pro)
por: Tan, Haozhou, et al.
Publicado: (2023) -
Rational Design of Hybrid SARS-CoV-2 Main Protease
Inhibitors Guided by the Superimposed Cocrystal Structures with the
Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir
por: Xia, Zilei, et al.
Publicado: (2021) -
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020) -
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
por: Ma, Chunlong, et al.
Publicado: (2020)